bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc.
Your view on BIAFW
Overview
What the company does, where it operates, and who runs it.
About bioAffinity Technologies, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Maria Zannes
- Headquarters
- 3300 Nacogdoches Road, San Antonio, TX, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Maria Zannes
- Headquarters
- 3300 Nacogdoches Road, San Antonio, TX, US
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for bioAffinity Technologies, Inc., and the rating behind it. BIAFW last traded at $0.34; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for bioAffinity Technologies, Inc.. Starting points for bioAffinity Technologies, Inc.: EPS -$43.58, beta -1.05 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for bioAffinity Technologies, Inc.. bioAffinity Technologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for bioAffinity Technologies, Inc.. Trailing twelve-month EPS for bioAffinity Technologies, Inc. stands at -$43.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for bioAffinity Technologies, Inc.. bioAffinity Technologies, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
bioAffinity Technologies, Inc. valued side by side against its closest peers. bioAffinity Technologies, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold bioAffinity Technologies, Inc., and how their positions are changing. At a $12.1M market value, institutional positions materially move bioAffinity Technologies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by bioAffinity Technologies, Inc. executives and directors. Shares of bioAffinity Technologies, Inc. have traded between $0.06 and $0.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming bioAffinity Technologies, Inc.. bioAffinity Technologies, Inc. is a $12.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming bioAffinity Technologies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for bioAffinity Technologies, Inc.. Coverage tracks bioAffinity Technologies, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.